Comparison of the efficacy of Janus kinase inhibitors and adalimumab in rheumatoid arthritis: a meta-analysis
Authors' conclusion
JAKi generally offers better efficacy than ADA in the treatment of RA, though this advantage appears to be influenced by the duration of treatment.
Study context
- Population
- Patients with rheumatoid arthritis (RA)
- Participants
- 4,048 patients6 studies
- Comparison
- Janus kinase inhibitors (JAKi) vs and adalimumab (ADA)
- Outcome
- Efficacy of JAKi vs ADA: ACR20, ACR50, ACR70, CDAI, SDAI and DAS28-4(CRP) response
Methodological detailssystematic search of PubMed, Web of Science, Embase and the Cochrane Library (to May 2024), Review Manager (RevMan) analysis, PubMed, Web of Science, Embase and Cochrane Library searched as of May 2024; analysed with RevMan
- Systematic search of PubMed, Web of Science, Embase and the Cochrane Library (to May 2024)
- RevMan analysis
- PubMed, Web of Science, Embase and Cochrane Library searched as of May 2024; analysed with RevMan
Pooled result
As reported in the abstract
- ACR50
- RR 1.20; P = 0.02
- ACR70
- RR 1.24; P = 0.03
- Clinical Disease Activity Index (CDAI)
- RR 1.17; P = 0.01
- Simplified Disease Activity Index (SDAI)
- RR 1.19; P = 0.006
Further pooled results
| Outcome | Estimate | P value |
|---|---|---|
| ACR50 and ACR70 over 52 weeks (longitudinal analysis)JAKi vs ADA | RR, ACR50 1.16 | P = 0.19 |
| ACR50 and ACR70 over 52 weeks (longitudinal analysis)JAKi vs ADA | RR, ACR70 1.10 | P = 0.26 |
| JAKi subgroups: tofacitinib and other JAKi vs ADATofacitinib vs ADA | RR 1.49 | P = 0.003 |
| JAKi subgroups: tofacitinib and other JAKi vs ADAOther JAKi vs ADA · no significant difference | RR 1.19 | P = 0.11 |
Original publication
Comparison of the efficacy of Janus kinase inhibitors and adalimumab in rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. Published 15 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →